Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
Table 3
Side effects of different treatment regiments.
RMAB
RMMB
RACB
P1
P2
P3
Side effects of treatment, (%)
36 (30.0)
45 (37.5)
48 (40.0)
0.219
0.104
0.691
Nausea
8 (6.7)
18 (15.0)
3 (2.5)
0.038
0.123
0.001
Vomiting
1 (0.8)
2 (1.7)
1 (0.8)
—
1.000
1.000
Epigastric discomfort
13 (10.8)
24 (20.0)
12 (10.0)
0.049
0.833
0.030
Dizziness
8 (6.7)
24 (20.0)
3 (2.5)
0.002
0.123
0.000
Insomnia
3 (2.5)
5 (4.2)
3 (2.5)
0.472
1.000
0.722
Diarrhea
10 (8.3)
9 (7.5)
16 (13.3)
0.811
0.213
0.139
Darkened stool
30 (25.0)
29 (24.2)
33 (27.5)
0.811
0.660
0.555
Taste disorder
3 (2.5)
4 (3.3)
41 (34.2)
1.0000
0.000
0.000
Skin rash
0
0
1
Tinnitus
0
0
1
Arthralgia
0
1
0
P1: RMAB vs. RMMB; P2: RMAB vs. RACB; P3: RMMB vs. RACB. RMAB group: rabeprazole plus minocycline, amoxicillin, and bismuth; RMMB group: rabeprazole plus minocycline, metronidazole, and bismuth; RACB group: rabeprazole plus amoxicillin, clarithromycin, and bismuth.
